Designs for Single- or Multiple-Agent Phase I Trials

DOI10.1111/J.0006-341X.2004.00215.XMaRDI QIDQ3445286zbMATHOpenAlexWikidataFDO

Authors Mark R. Conaway, Stephanie Dunbar, Shyamal D. Peddada

Publication date 11 June 2007

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.0006-341x.2004.00215.x

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Continual reassessment method for partial ordering
• Dose-finding with two agents in phase I oncology trials
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Design and Analysis of Phase I Clinical Trials
• Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses

Cites work

• A Random Walk Rule for Phase I Clinical Trials
• Clinical Trials
• Confidence interval estimation subject to order restrictions
• Continual Reassessment Method: A Likelihood Approach
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Dose finding using the biased coin up-and-down design and isotonic regression
• Dose-finding with two agents in phase I oncology trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials

Cited in

(17)

• A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
• Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses
• Adaptive clinical trial designs for phase I cancer studies
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies
• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Cumulative cohort design for dose-finding
• Dose-finding with two agents in phase I oncology trials
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• A phase I dose-finding study based on polychotomous toxicity responses
• Continual reassessment method for partial ordering

This page was built for publication: Designs for Single- or Multiple-Agent Phase I Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3445286)